Co-Diagnostics (DE:C970)
NASDAQ:C970
C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€14.96M
Enterprise Value€3.32M
Total Cash (Recent Filing)€8.23M
Total Debt (Recent Filing)€2.03M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.26
Shares Outstanding3,685,314
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
Platform And Pipeline DiversificationA diversified product roadmap and platform-level capabilities (cloud connectivity and ML) reduce reliance on any single assay and increase stickiness with customers. Platform breadth supports cross-selling of consumables and instruments, improving long-term revenue resilience once clinical and regulatory wins convert to scale.
India Manufacturing And Regulatory PresenceA licensed India manufacturing and commercial footprint with multiple CDSCO clearances meaningfully lowers regulatory and distribution barriers in a large addressable market. Local manufacturing and existing lab relationships provide durable channels to scale PCR test sales and recurring consumable demand across South Asia.
Completed Upper-respiratory Enrollment And 510(k) PathFinishing enrollment is a structural regulatory milestone that enables a formal 510(k) pathway and potential CLIA-waived point-of-care clearance. If cleared, this expands addressable markets and facilitates recurring reagent sales and instrument placements, creating long-term commercial leverage beyond one-off studies.
Bears Say
Collapsed Revenue And Sustained LossesA multi-year collapse in revenue has erased scale economics and turned historical profits into persistent operating losses. Without meaningful, sustained commercial uptake, fixed R&D and G&A costs will continue to depress margins, making durable profitability unlikely until top-line growth is reestablished.
Severe Cash Burn And Negative Operating Cash FlowLarge negative operating cash flow relative to minimal revenue creates an ongoing liquidity gap. Persistent cash burn forces dependence on external financing, which can delay commercialization initiatives and constrain capital-intensive build-outs, elevating the structural risk to execution and program continuity.
Eroded Equity Base And Dilution RiskSubstantial equity erosion reduces the balance-sheet cushion and limits borrowing capacity, making the company more reliant on dilutive equity or strategic transactions to fund operations. This structural weakening constrains strategic flexibility and raises the likelihood of future dilution or restricted capital options.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €14.96M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on May 14, 2026. The company reported -€3.507 earnings per share for the quarter, missing the consensus estimate of N/A by -€3.507.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Overvalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 3,685,314 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€3.507 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that designs, produces, and globally markets specialized reagents. These components are integral to diagnostic tests that identify and analyze nucleic acid molecules. The company's product portfolio features the Co-Dx PCR platform, enabling Polymerase Chain Reaction (PCR) testing for patients in both clinical (point-of-care) and home settings. They offer an extensive range of PCR diagnostic tests for numerous conditions, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Beyond human health, Co-Diagnostics develops three distinct multiplexed tests for screening mosquitos to detect disease-carrying pathogens. Their advanced molecular tools also serve broader applications, encompassing infectious disease detection, liquid biopsy for cancer screening, and agricultural uses such as identifying genetic traits in plant and animal genomes. Complementing these offerings is a portable diagnostic device, specifically engineered to make PCR testing accessible directly to patients in various settings. The company was founded in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and regulatory progress across multiple strategic fronts — completed upper respiratory enrollment (>1,400 patients), India manufacturing license and expanded TAM (~$13B), TB clinical start timing, land allocation in Saudi Arabia, and manufacturing automation plans (~4x efficiency). However, the company still reports very limited absolute revenue, a negative gross margin, widening net loss and adjusted EBITDA losses, and a substantial cash decline to $8.2M with an anticipated need for additional capital. Program-level uncertainties (COVID prevalence affecting submission scope), unfinished manufacturing rollouts and no assurance on strategic transactions temper the positive operational milestones. Overall, operational momentum is clear, but financial constraints and execution risks balance the outlook.View all DE:C970 earnings summariesSintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Options Prices
Currently, No data available
---